News C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-01 pm EST			5-day change	1st Jan Change
1.600 ^USD	-1.84%		+4.58%	-72.88%

Nov. 20	C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	CI
Nov. 07	North American Morning Briefing : Higher Bond -2-	DJ

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed, Refractory Multiple Myeloma	Nov. 29	AQ
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma	Nov. 28	GL
C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors	Nov. 20	CI
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment	Nov. 20	GL
North American Morning Briefing : Higher Bond -2-	Nov. 07	DJ
Morgan Stanley Upgrades C4 Therapeutics to Equalweight From Underweight, Cuts Price Target to $1 From $3	Nov. 06	MT
BMO Capital Adjusts Price Target on C4 Therapeutics to $16 From $18, Keeps Outperform Rating	Nov. 03	MT
HC Wainwright Adjusts Price Target on C4 Therapeutics to $7 From $17, Keeps Buy Rating	Nov. 02	MT
C4 Therapeutics : CTOS 2023 - CFT8634 Phase 1 Dose Escalation	Nov. 01	PU
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 01	GL
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
TPD Summit: Addressing Challenging Therapeutic Targets Using Innovative Bifunctional Degrader Approaches TPD Summit	Oct. 31	PU
Top Premarket Decliners	Oct. 12	MT
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors	Oct. 12	AQ
C4 Therapeutics : Corporate Presentation – October 2023	Oct. 11	PU
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma	Oct. 11	GL
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma	Oct. 11	AQ
C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455	Oct. 11	CI
ImmunoGen Names Lauren White CFO	Sep. 18	MT
C4 Therapeutics Appoints Kendra Adams as Finance Chief	Sep. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

News C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Summary

Filters